Inozyme Pharma
Price & Volume
Stats
See more52W Range | $0.72-$6.24 |
Market Cap | $66.2M |
Shares Short | 4M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$1.54 |
News
See moreYahoo Finance • last month
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
Yahoo Finance • 2 months ago
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
Yahoo Finance • last year
Inozyme Pharma to Participate in Upcoming Investor Conferences
Yahoo Finance • last year
Inozyme Pharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
About
CEO | Dr. Douglas A. Treco Ph.D. |
CFO | Mr. Sanjay S. Subramanian M.B.A., M.S. |
Address | 321 Summer Street, Boston, MA, United States, 02210 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 67 |
